Lovaza is manufactured by GlaxoSmithKline. Currently, no generic versions are available in the United States.
When Will Generic Lovaza Be Available?
Although the first patent for Lovaza expired in March 2013, no generic versions are available. This suggests that another, later-expiring patent may still be providing protection for the drug. The next patent is set to expire in April 2017. This is the earliest predictable date that a generic version could become available.
However, there are other circumstances that could come up to extend or shorten the exclusivity period of Lovaza. This could include such things as lawsuits or other patents for specific Lovaza uses.
Is Fish Oil a Generic for Lovaza?
It is important to point out that non-prescription fish oil supplements are not equivalent to Lovaza. Lovaza is an FDA-approved prescription fish oil medication.
Some people wonder why they should take Lovaza, when there are inexpensive non-prescription fish oil dietary supplements that seem to be just as good. There are several advantages of Lovaza over such supplements.
For example, it's important to note that the cheaper supplements almost always have a low concentration of EPA and DHA, regardless of the strength on the label. This can be misleading; it may take numerous 1000 mg supplement capsules to have the same amount of EPA and DHA as a single Lovaza 1000 mg capsule.
When this is taken into consideration, much of the cost advantage of the inexpensive supplements is lost.
Perhaps more importantly, dietary supplements are not regulated as strictly as prescription drugs (like Lovaza). In fact, they are regulated as foods. This means that some supplements could potentially be contaminated or could have less (or more) of the active ingredients than stated on the label.
Lovaza is made using a 5-step refinement process that removes impurities, ensuring a safe and pure product. Also, this refinement process removes some of the fish oil components that cau
Both Pronova and GlaxoSmithKline PLC — which has the marketing rights for Lovaza in the U.S. and Puerto Rico and was not involved in the litigation — announced in separate press releases Wednesday that the parties' settlement grants Apotex a license to enter the U.S. market with a generic version of Lovaza in the first quarter of 2015, or earlier depending on certain undisclosed circumstances.
GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents
Issued: Tuesday 29 May 2012, London, UK
"The Lovaza patents are owned by Pronova and licensed to GSK in the United States and Puerto Rico, and cover compositions and methods of using omega-3 fatty acids. The ‘667 patent expires in April 2017 and the ‘077 patent expires in March 2013. Pronova, via its wholly-owned subsidiary Pronova BioPharma Norge AS, filed the patents infringement lawsuit against Teva and Par in April 2009.
Previously, Pronova had entered into an agreement in March 2011 with Apotex Corp. and Apotex Inc. (collectively “Apotex”), to settle their patent litigation in the United States related to Lovaza. The settlement grants Apotex a license to enter the US market with a generic version of Lovaza in the first quarter of 2015, or earlier depending on certain circumstances. '
Twoconfused ---google Apotek , Teva and GSK --- Generic Lovaza is not far off --to be made by Apotek I believe ( maybe you already know this ?? ) anyway --generic Lovaza will not be approved for the Anchor market ----and thats where the $ are ( or at least we hope )